Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
about
Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma.Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myelomaClinical challenges: Myeloma and concomitant type 2 diabetes.Clinical challenges: myeloma and concomitant type 2 diabetesNew Treatment Approaches for Older Adults with Multiple Myeloma.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.Multiple myeloma and diabetes.Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
P2860
Q33437045-9102E682-4EE3-47AB-9474-0D50FB0580FDQ33993196-2AD4E8DE-7D71-498F-B977-3A3AD6A2BA43Q36149549-858B1C2E-0A56-4205-9202-426DCC65587BQ37274353-BF4BE87A-24EA-4209-8D94-9E5E0CABA824Q37467309-F3E736CC-88DA-4008-B0BB-B377998028F8Q37552667-C209BF63-DBAA-45F0-AFB0-EF602A93AE5FQ38048281-D02DCF6B-AD90-4736-9A5E-A7E0FEB68BE1Q38065298-732F6DB7-FBA1-43DB-BDD5-0C1651744AABQ39763096-3D77E245-4EB3-4B02-9CF3-50F27BE26E1EQ40550022-C0877615-1ACE-41AB-9CF3-017F67645A4BQ44962377-246A7CEE-EF0D-4A1E-8451-EC73466A7375
P2860
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Consensus guidelines for the o ...... treatment of multiple myeloma.
@en
Consensus guidelines for the o ...... treatment of multiple myeloma.
@nl
type
label
Consensus guidelines for the o ...... treatment of multiple myeloma.
@en
Consensus guidelines for the o ...... treatment of multiple myeloma.
@nl
prefLabel
Consensus guidelines for the o ...... treatment of multiple myeloma.
@en
Consensus guidelines for the o ...... treatment of multiple myeloma.
@nl
P2093
P1433
P1476
Consensus guidelines for the o ...... treatment of multiple myeloma.
@en
P2093
F Leal da Costa
M Delforge
R Garcia Sanz
P304
P356
10.1007/S00277-010-0925-1
P577
2010-03-16T00:00:00Z